Zimmer Biomet stock price ZBH share today Chart

Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC.

Provides a general description of the business conducted by this company.

Recently Viewed Tickers

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares. Additional information about your broker can be found by clicking here.

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Related Stocks

Alternative Assets.Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been https://g-markets.net/helpful-articles/can-you-start-trading-forex-with-just-100-2/ issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”). These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured.

This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.17% per year.

Zimmer Biomet issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of $7.40-$7.50 for the period, compared to the consensus estimate of $7.06. The company issued revenue guidance of $7.29 billion-$7.36 billion, compared to the consensus revenue estimate of $7.14 billion. As of June 15th, there was short interest totaling 3,810,000 shares, an increase of 27.0% from the May 31st total of 3,000,000 shares. Based on an average daily trading volume, of 1,410,000 shares, the short-interest ratio is currently 2.7 days. The company's leadership team is led by President and CEO Bryan Hanson, who has been in his current role since 2017.

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Third quarter net sales from continuing operations of $1.670 billion decreased 0.9% and increased 5.0% on a constant currency1 basis Third quarter diluted earnings per share from continuing operations...

Robert W. Baird Sticks to Their Buy Rating for Zimmer Biomet Holdings (ZBH)

Changes in regulatory requirements could increase the costs and time required to bring new products to market, affecting Zimmer Biomet's ability to innovate and compete. In addition, insurance and hospital reimbursement policy changes could also impact the demand for Zimmer Biomet's products. Over the past few years, Zimmer Biomet has reported steady financial performance. The company has reported increased revenue and profit margin for the past several years while also reporting a debt-to-equity ratio indicating a relatively low debt level. In 2021, the company also announced a share repurchase program of up to $1 billion, demonstrating its commitment to returning value to shareholders.

• This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.
• Zimmer Biomet is one of the largest companies in the industry, with a strong presence in the joint reconstruction, spine, dental, and sports medicine markets.
• Since 1988 it has more than doubled the S&P 500 with an average gain of +24.17% per year.
• Amid recessionary concerns, investing in medical stock Abbott Laboratories (ABT) could be wise given its sound financials and the...

Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.

Zimmer Biomet to Present at Bank of America Securities and Jefferies Healthcare Conferences

Bryan Hanson has an approval rating of 87% among the company's employees. 66.0% of employees surveyed would recommend working at Zimmer Biomet to a friend. Sign-up to receive the latest news and ratings for Zimmer Biomet and its competitors with MarketBeat's FREE daily newsletter. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. The musculoskeletal healthcare company continues to try to turn things around, with limited success in the first quarter.

Hanson has over 30 years of experience in the medical device industry and has held various executive positions in leading medical device companies. Additionally, Zimmer Biomet's executive team includes Chief Financial Officer Suketu Upadhyay and Chief Operating Officer Ivan Tornos. Zimmer Biomet Holdings Inc is a medical technology company that designs, develops and manufactures a wide range of orthopedic and musculoskeletal products. With headquarters in Warsaw, Indiana, the company was formed in 2015 after the merger of Zimmer Holdings and Biomet Inc, two of the world's leading companies in the orthopedic industry. Zimmer Biomet's mission is to help people alleviate pain, regain mobility and improve the quality of life for patients worldwide. Some of the biggest medical device companies' stocks have dropped to attractive prices due to the current COVID-19 pandemic.

Banking services and bank accounts are offered by Jiko Bank, a division of Mid-Central National Bank, Member FDIC. You can find your newly purchased ZBH stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

The Barchart Technical Opinion widget shows you today's overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. One of the most significant risks facing Zimmer Biomet is the potential for regulatory changes that could impact the industry.

For example, the increasing popularity of non-surgical treatments for orthopedic conditions could affect the demand for joint replacement products. Zimmer Biomet's stock performance has been mixed over the past few years. In early 2020, the company's stock price experienced a sharp decline due to the COVID-19 pandemic, but since then, it has rebounded and continues to experience volatility. The company's hip and knee replacement products continue to enjoy solid demand.

• One share of ZBH stock can currently be purchased for approximately $142.65.
• You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.
• JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries.
• The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.

These returns cover a period from January 1, 1988 through May 15, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals. Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business. Amid recessionary concerns, investing in medical stock Abbott Laboratories (ABT) could be wise given its sound financials and the...

Financial Calendars

An indication of interest to purchase securities involves no obligation or commitment of any kind. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. You should consult your legal, tax, or financial advisors before making any financial decisions.